Skip to content

Establishment Labs ESTA Prepaid U.S. clinical trial costs

Other financials

Income statement

See full
Revenue$59.9M+44.7%
Gross profit$42.3M+52.2%
Operating income-$6.5M+61.6%
Net income-$13.4M+35.4%
EPS (diluted)-$0.45+35.7%

Balance sheet

See full
Cash & equivalents$68.1M-1.6%
Total debt$252.7M+12.0%
Total equity$14.8M-61.7%
Total assets$351.0M+5.3%

Cash flow

See full
Operating cash flow-$4.3M+79.2%
CapEx$1.9M+146%
Free cash flow-$6.2M+71.3%

Valuation

See full
Market cap$2.56B+41.4%
Enterprise value$2.75B+38.7%
P/S11.2×+0.5×

Profitability

See full
Gross margin70.1%+3.7pp
Operating margin-12.4%-4.8pp
Net margin-19.1%-7.4pp
FCF margin-18.1%-6.6pp

Returns & leverage

See full
Return on equity-164%-17.8pp
Debt / equity17.1×+11.2×
Current ratio-0.4×

Where this comes from

Reported directly by Establishment Labs in its filing.

Tagged under the XBRL concept esta:PrepaidClinicalTrialCostsCurrent.

The official record: Establishment Labs’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Establishment Labs's prepaid u.s. clinical trial costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Establishment Labs's prepaid U.S. clinical trial costs?
Establishment Labs (ESTA) reported prepaid U.S. clinical trial costs of $114K in Q1 2026.
How has Establishment Labs's prepaid U.S. clinical trial costs changed year-over-year?
Establishment Labs's prepaid U.S. clinical trial costs decreased by 18.0% year-over-year, from $139K to $114K.
What is the long-term trend for Establishment Labs's prepaid U.S. clinical trial costs?
Over 4 years (2021 to 2025), Establishment Labs's prepaid U.S. clinical trial costs has grown at a -26.5% compound annual growth rate (CAGR), from $412K to $120K.